> Skip repeated content

Research

Ultrasound-Guided Platelet Rich Plasma versus Whole Blood Injection for the Treatment of Gluteus Medius Tendinopathy: A Double-Blind Randomized Controlled Study

IRB Number: 2015-184
(inactive trial)

Institutional Review Board, Hospital for Special Surgery

June 16, 2017

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

Peter J. Moley, MD

Co-Investigators

James F. Wyss, MD, PT
Gregory Lutz, MD
Jonathan Kirschner, MD
Eric Holder, MD
Jessica Hettler, PT
Jennifer Cheng, PhD

Summary

Gluteus medius tendinopathy, which is often referred to as Greater Trochanteric Pain Syndrome, is characterized by pain in the lateral aspect of the hip that is aggravated by side lying, stair climbing, and walking. Treatment is currently limited to lifestyle modifications, corticosteroid injections, physical therapy, and open and endoscopic surgical repair. Platelet-rich plasma (PRP) injections contain important growth factors that are essential in the healing and tissue formation processes. However, the extent to which PRP is more efficacious than whole blood in tendinopathy remains unclear. In this double-blind randomized trial, patients will be allocated to receive an injection of either PRP or whole blood. Post-procedure assessments will occur at 6 weeks, 3 months, 6 months, 9 months, and 1 year. Study-specific physical therapy sessions will occur at 2 weeks and 6-8 weeks post-procedure.

Inclusion/Exclusion Criteria

Gluteus medius tendinopathy, which is often referred to as Greater Trochanteric Pain Syndrome, is characterized by pain in the lateral aspect of the hip that is aggravated by side lying, stair climbing, and walking. Treatment is currently limited to lifestyle modifications, corticosteroid injections, physical therapy, and open and endoscopic surgical repair. Platelet-rich plasma (PRP) injections contain important growth factors that are essential in the healing and tissue formation processes. However, the extent to which PRP is more efficacious than whole blood in tendinopathy remains unclear. In this double-blind randomized trial, patients will be allocated to receive an injection of either PRP or whole blood. Post-procedure assessments will occur at 6 weeks, 3 months, 6 months, 9 months, and 1 year. Study-specific physical therapy sessions will occur at 2 weeks and 6-8 weeks post-procedure.

Contact Information

Jennifer Cheng
chengj@hss.edu
646.714.6870

Nicole Hurwitz
hurwitzn@hss.edu
212.774.7386